Your browser doesn't support javascript.
loading
Is Impact of Statin Therapy on All-Cause Mortality Different in HIV-Infected Individuals Compared to General Population? Results from the FHDH-ANRS CO4 Cohort.
Lang, Sylvie; Lacombe, Jean-Marc; Mary-Krause, Murielle; Partisani, Marialuisa; Bidegain, Frédéric; Cotte, Laurent; Aslangul, Elisabeth; Chéret, Antoine; Boccara, Franck; Meynard, Jean-Luc; Pradier, Christian; Roger, Pierre-Marie; Tattevin, Pierre; Costagliola, Dominique; Molina, Jean-Michel.
Afiliación
  • Lang S; Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP UMRS 1136), F75013, Paris, France.
  • Lacombe JM; Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP UMRS 1136), F75013, Paris, France.
  • Mary-Krause M; Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP UMRS 1136), F75013, Paris, France.
  • Partisani M; Hôpitaux Universitaires de Strasbourg, Le Trait D'Union, centre de soins de l'infection par le VIH, Strasbourg, France.
  • Bidegain F; APHP, Hôpital Avicenne, service de maladie infectieuse, Bobigny, France.
  • Cotte L; Hospices Civils de Lyon, Hôpital de la Croix Rousse, service des maladies infectieuses et tropicales, Lyon, France; INSERM U1052, Lyon, France.
  • Aslangul E; APHP, Hôtel Dieu, service de médecine interne, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
  • Chéret A; APHP, Hôtel Necker, laboratoire de virologie, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, EA 3620, Paris, France; Centre hospitalier de Tourcoing, service des maladies infectieuses, Tourcoing, France.
  • Boccara F; APHP, Hôpital Saint-Antoine, service de cardiologie, Paris, France; Sorbonne Universités, UPMC Univ Paris 06, INSERM (UMRS 938), F75012, Paris, France.
  • Meynard JL; APHP, Hôpital Saint-Antoine, service des maladies infectieuses et tropicales, Paris, France.
  • Pradier C; Centre hospitalier universitaire de Nice, groupe hospitalier l'Archet, service de santé publique, Nice, France.
  • Roger PM; Centre hospitalier universitaire de Nice, groupe hospitalier l'Archet, service d'infectiologie, Nice, France; Université de Nice, Sophia-Antipolis, France.
  • Tattevin P; Hôpital Universitaire Pontchaillou, service des maladies infectieuses et USI, Rennes, France.
  • Costagliola D; Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP UMRS 1136), F75013, Paris, France.
  • Molina JM; APHP, Hôpital Saint-Louis, service des maladies infectieuses et tropicales, Paris, France; Université de Paris Diderot Paris 7, Sorbonne Paris Cité, INSERM (U941), Paris, France.
PLoS One ; 10(7): e0133358, 2015.
Article en En | MEDLINE | ID: mdl-26200661
BACKGROUND: The effect of statins on all-cause mortality in the general population has been estimated as 0.86 (95%CI 0.79-0.94) for primary prevention. Reported values in HIV-infected individuals have been discordant. We assessed the impact of statin-based primary prevention on all-cause mortality among HIV-infected individuals. METHODS: Patients were selected among controls from a multicentre nested case-control study on the risk of myocardial infarction. Patients with prior cardiovascular or cerebrovascular disorders were not eligible. Potential confounders, including variables that were associated either with statin use and/or death occurrence and statin use were evaluated within the last 3 months prior to inclusion in the case-control study. Using an intention to continue approach, multiple imputation of missing data, Cox's proportional hazard models or propensity based weighting, the impact of statins on the 7-year all-cause mortality was evaluated. RESULTS: Among 1,776 HIV-infected individuals, 138 (8%) were statins users. During a median follow-up of 53 months, 76 deaths occurred, including 6 in statin users. Statin users had more cardiovascular risk factors and a lower CD4 T cell nadir than statin non-users. In univariable analysis, the death rate was higher in statins users (11% vs 7%, HR 1.22, 95%CI 0.53-2.82). The confounders accounted for were age, HIV transmission group, current CD4 T cell count, haemoglobin level, body mass index, smoking status, anti-HCV antibodies positivity, HBs antigen positivity, diabetes and hypertension. In the Cox multivariable model the estimated hazard ratio of statin on all-cause mortality was estimated as 0.86 (95%CI 0.34-2.19) and it was 0.83 (95%CI 0.51-1.35) using inverse probability treatment weights. CONCLUSION: The impact of statin for primary prevention appears similar in HIV-infected individuals and in the general population.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Infecciones por VIH / Inhibidores de Hidroximetilglutaril-CoA Reductasas Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies País/Región como asunto: Europa Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2015 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Infecciones por VIH / Inhibidores de Hidroximetilglutaril-CoA Reductasas Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies País/Región como asunto: Europa Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2015 Tipo del documento: Article